Tegsedi
Amyloidosis, Hereditary
Dormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Amyloidosis, Hereditary cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Patisiran Alnylam Pharmaceuticals | Phase 3 | A |
Revusiran Alnylam Pharmaceuticals | Phase 3 | BB |
Patisiran Alnylam Pharmaceuticals | Phase 3 | BB |
Patisiran Alnylam Pharmaceuticals | Phase 3 | BB |
Revusiran Alnylam Pharmaceuticals | Phase 3 | BB |
View all 12 →
Same molecule, other indications
Tegsedi is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →